Tomefa E Asempa David P Nicolau
10.2147/CIA.S149089
Clin Interv Aging
2017 Oct 24;12:1799-1809.
clostridium difficile aging bezlotoxumab elderly fecal microbiota transplant recurrence risk factors treatment
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/29123385/
Clostridium Infections / physiopathology Clostridium Infections / therapy
Clostridium Infections / physiopathology Clostridium Infections / therapy Review Aged Anti-Bacterial Agents / therapeutic use Antibodies, Monoclonal / therapeutic use Antibodies, Neutralizing / therapeutic use Broadly Neutralizing Antibodies Clostridioides difficile Clostridium Infections / economics Clostridium Infections / epidemiology Fecal Microbiota Transplantation / methods Health Expenditures Humans Prospective Studies Recurrence Retrospective Studies Risk Factors Severity of Illness Index Anti-Bacterial Agents Antibodies, Monoclonal Antibodies, Neutralizing Broadly Neutralizing Antibodies bezlotoxumab
PMC5661493
29123385
Clostridium difficile infection in the elderly: an update on management
2017